Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 5, 2013, Pages 855-860

  Lin, Brian ^a   Ha, Nghiem B ^a,c   Liu, Anne ^c   Trinh, Huy N ^a,b   Nguyen, Huy A ^b   Nguyen, Khanh K ^b   Ahmed, Aijaz ^c   Keeffe, Emmet B ^c   Garcia, Ruel T ^a,b   Garcia, Gabriel ^c   Nguyen, Mindie H ^c  

^a Pacific Health Foundation   (United States)

^b San Jose Gastroenterology   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HBeAg seroconversion rates; HBeAg positive; Predictors of HBeAg seroconversion

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; ASIAN; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG DOSE INCREASE; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION;

EID: 84876984773     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12108     Document Type: Article

References (37)

1. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-1745.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956.
3. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
4. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Keeffe EB, Dieterich DT, Han SH etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 2008; 6: 1315-1341; quiz 286.
6. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-283.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
9. Liaw YF. HBeAg seroconversion as an important end point in the4 treatment of chronic hepatitis B. Hepatol. Int. 2009; 3: 425-433.
10. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig. Dis. Sci. 2010; 55: 2727-2734.
11. Yoon SK, Jang JW, Kim CW etal. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005; 48: 341-349.
12. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-68.
13. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-1263.
14. Lai CL, Leung N, Teo EK etal. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536.
15. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
16. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-1010.
17. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-2588.
18. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J. Gastroenterol. 2007; 13: 4264-4267.
19. Hou J, Yin YK, Xu D etal. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454.
20. Sung JJ, Lai JY, Zeuzem S etal. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 2008; 48: 728-735.
21. Yao G, Chen C, Lu W etal. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol. Int. 2008; 2: 486-493.
22. Marcellin P, Chang TT, Lim SG etal. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003; 348: 808-816.
23. Chan HL, Heathcote EJ, Marcellin P etal. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 2007; 147: 745-754.
24. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-2455.
25. Leung N, Peng CY, Hann HW etal. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72-79.
26. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am. J. Gastroenterol. 2011; 106: 1264-1271.
27. Yao G, Chen C, Lu W etal. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol. Int. 2007; 1: 365-372.
28. Liu CJ, Chen PJ, Lai MY etal. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int. 2006; 26: 949-955.
29. Perrillo RP, Lai CL, Liaw YF etal. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194.
30. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J. Gastroenterol. Hepatol. 2003; 18: 246-252.
31. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 2008; 49: 634-651.
32. Ha NB, Garcia RT, Trinh HN etal. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig. Dis. Sci. 2011; 56: 2423-2431.
33. Hongthanakorn C, Chotiyaputta W, Oberhelman K etal. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-1863.
34. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am. J. Med. 2004; 116: 829-834.
35. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol. Int. 2007; 1: 415-430.
36. Woo G, Tomlinson G, Nishikawa Y etal. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
37. Asselah T, Lada O, Marcellin P. [Treatment of chronic hepatitis B]. Rev. Prat. 2011; 61: 45-51.